PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients. This study aims to identify safety and efficacy of prophylactic Tocilizumab treatment. In particular, to explore whether prophylactic Tocilizumab treatment can decrease the incidence and severity of CRS (and subsequent eventual neurotoxicity) following CAR-T-treatment.

Trial Details

NCT ID
NCT06430736
Phase
PHASE2
Sponsor
Insel Gruppe AG, University Hospital Bern
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Tocilizumab before CAR-T cell infusion
  • Tocilizumab at emerging CRS
Locations (sample)
  • Bern, Canton of Bern, Switzerland|46.94809,7.44744

Key Eligibility Criteria

  • Patients planned to receive commercial CAR-T treatment for all registered indications comprising lymphomas, leukemias or myeloma at a single academ…
  • With written informed consent
  • Considered by the investigator to be clinically fit for this treatment
  • Patients aged ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →